Posted by Michael Wonder on 20 May 2017
Highlights from the CHMP 15-18 May 2017 meeting
19 May 2017 - Eleven medicines recommended for approval, including one advanced therapy medicine
The European CHMP recommended eleven medicines, including one advanced therapy medicinal product, for approval at its May 2017 meeting.
The CHMP recommended granting a marketing authorisation for the ATMP Spherox (spheroids of human autologous matrix-associated chondrocytes) to treat adult patients who have symptomatic articular cartilage defects in the knee where the size of the affected area is no larger than 10 cm². For more information, please see the press release in the grid below.
The CHMP recommended granting a marketing authorisation for Oxervate (cenegermin) for the treatment of moderate to severe neurotrophic keratitis. Oxervate has an orphan designation.
